{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:00:30Z","timestamp":1760299230847,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR000067"],"award-info":[{"award-number":["UL1TR000067"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00280-015-2884-7","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T20:28:23Z","timestamp":1444768103000},"page":"1259-1265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma"],"prefix":"10.1007","volume":"76","author":[{"given":"Matthew D.","family":"Galsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah M.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Argiriadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costantine","family":"Albany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiev","family":"Gimpel-Tetra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaibhav","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che-Kai","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William K.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,13]]},"reference":[{"issue":"10","key":"2884_CR1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","volume":"30","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt J, von der Maase H, Mead GM et al (2012) Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol 30(10):1107\u20131113. doi:\n                    10.1200\/JCO.2011.38.6979","journal-title":"J Clin Oncol"},{"issue":"1","key":"2884_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","volume":"42","author":"CN Sternberg","year":"2006","unstructured":"Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42(1):50\u201354","journal-title":"Eur J Cancer"},{"issue":"9","key":"2884_CR3","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S1470-2045(10)70086-3","volume":"11","author":"G Sonpavde","year":"2010","unstructured":"Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11(9):861\u2013870. doi:\n                    10.1016\/S1470-2045(10)70086-3","journal-title":"Lancet Oncol"},{"issue":"27","key":"2884_CR4","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","volume":"27","author":"J Bellmunt","year":"2009","unstructured":"Bellmunt J, Theodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27(27):4454\u20134461","journal-title":"J Clin Oncol"},{"issue":"(15_suppl)","key":"2884_CR5","first-page":"4525","volume":"31","author":"MD Galsky","year":"2013","unstructured":"Galsky MD, Chowdhury S, Bellmunt J et al (2013) Treatment patterns and outcomes in \u201creal world\u201d patients (pts) with metastatic urothelial cancer (UC). ASCO Meet Abstr 31((15_suppl)):4525","journal-title":"ASCO Meet Abstr"},{"issue":"2","key":"2884_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1517\/17425250802670508","volume":"5","author":"T Kurata","year":"2009","unstructured":"Kurata T (2009) Amrubicin for the treatment of advanced lung cancer. Expert Opin Drug Metab Toxicol 5(2):171\u2013180. doi:\n                    10.1517\/17425250802670508","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"2884_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1200\/JCO.2010.29.8851","volume":"29","author":"R Jotte","year":"2011","unstructured":"Jotte R, Conkling P, Reynolds C et al (2011) Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 29(3):287\u2013293. doi:\n                    10.1200\/JCO.2010.29.8851","journal-title":"J Clin Oncol"},{"issue":"35","key":"2884_CR8","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","volume":"32","author":"J Von Pawel","year":"2014","unstructured":"Von Pawel J, Jotte R, Spigel DR et al (2014) Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32(35):4012\u20134019. doi:\n                    10.1200\/JCO.2013.54.5392","journal-title":"J Clin Oncol"},{"issue":"1","key":"2884_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF00686485","volume":"30","author":"MJ Kuffel","year":"1992","unstructured":"Kuffel MJ, Reid JM, Ames MM (1992) Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 30(1):51\u201357","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"2884_CR10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/j.1349-7006.1998.tb00498.x","volume":"89","author":"T Yamaoka","year":"1998","unstructured":"Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89(10):1067\u20131073","journal-title":"Jpn J Cancer Res"},{"issue":"10","key":"2884_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/j.1349-7006.1998.tb00497.x","volume":"89","author":"T Noguchi","year":"1998","unstructured":"Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 89(10):1061\u20131066","journal-title":"Jpn J Cancer Res"},{"issue":"10","key":"2884_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1349-7006.1998.tb00496.x","volume":"89","author":"T Noguchi","year":"1998","unstructured":"Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 89(10):1055\u20131060","journal-title":"Jpn J Cancer Res"},{"issue":"3","key":"2884_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1023\/A:1005862730941","volume":"15","author":"T Suzuki","year":"1997","unstructured":"Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 15(3):219\u2013225","journal-title":"Invest New Drugs"},{"issue":"2","key":"2884_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1023\/A:1006088907271","volume":"16","author":"T Noda","year":"1998","unstructured":"Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T (1998) Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 16(2):121\u2013128","journal-title":"Invest New Drugs"},{"issue":"4","key":"2884_CR15","first-page":"475","volume":"28","author":"H Ohmori","year":"2001","unstructured":"Ohmori H, Yamato T, Asahi T (2001) Phase I study of amrubicin hydrochroride (SM-5887) for superficial bladder cancer in intravesical chemotherapy. Gan To Kagaku Ryoho 28(4):475\u2013482","journal-title":"Gan To Kagaku Ryoho"},{"issue":"4","key":"2884_CR16","first-page":"483","volume":"28","author":"T Tsushima","year":"2001","unstructured":"Tsushima T, Kobashi K, Akebi N et al (2001) Early phase II study of amrubicin (SM-5887) for superficial bladder cancer: a dose-finding study for intravesical chemotherapy. Gan To Kagaku Ryoho 28(4):483\u2013491","journal-title":"Gan To Kagaku Ryoho"},{"issue":"2","key":"2884_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. doi:\n                    10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"1","key":"2884_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1\u201310","journal-title":"Control Clin Trials"},{"issue":"11","key":"2884_CR19","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850\u20131855. doi:\n                    10.1200\/JCO.2009.25.4599","journal-title":"J Clin Oncol"},{"issue":"5","key":"2884_CR20","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","volume":"15","author":"JA McCaffrey","year":"1997","unstructured":"McCaffrey JA, Hilton S, Mazumdar M et al (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15(5):1853\u20131857","journal-title":"J Clin Oncol"},{"issue":"2","key":"2884_CR21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.1997.15.2.589","volume":"15","author":"RS Witte","year":"1997","unstructured":"Witte RS, Elson P, Bono B et al (1997) Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15(2):589\u2013593","journal-title":"J Clin Oncol"},{"issue":"21","key":"2884_CR22","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1200\/JCO.2005.03.6699","volume":"24","author":"CJ Sweeney","year":"2006","unstructured":"Sweeney CJ, Roth BJ, Kabbinavar FF et al (2006) Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24(21):3451\u20133457","journal-title":"J Clin Oncol"},{"issue":"10","key":"2884_CR23","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/sj.bjc.6603118","volume":"94","author":"S Culine","year":"2006","unstructured":"Culine S, Theodore C, De Santis M et al (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94(10):1395\u20131401. doi:\n                    10.1038\/sj.bjc.6603118","journal-title":"Br J Cancer"},{"issue":"(15_suppl)","key":"2884_CR24","first-page":"5011","volume":"32","author":"T Powles","year":"2014","unstructured":"Powles T, Vogelzang NJ, Fine GD et al (2014) Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). ASCO Meet Abstr 32((15_suppl)):5011","journal-title":"ASCO Meet Abstr"},{"key":"2884_CR25","doi-asserted-by":"crossref","unstructured":"Plimack ER, Bellmunt J, Gupta S et al (2015) Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol 33 (suppl; abstr 4502)","DOI":"10.1200\/jco.2015.33.15_suppl.4502"},{"key":"2884_CR26","doi-asserted-by":"crossref","unstructured":"Sequist L V, Cassier P, Varga A et al (2014) Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. In: American Association for Cancer Research 2014 Annual Meeting, p CT326","DOI":"10.1158\/1538-7445.AM2014-CT326"},{"issue":"(15_suppl)","key":"2884_CR27","first-page":"2501","volume":"32","author":"R Bahleda","year":"2014","unstructured":"Bahleda R, Dienstmann R, Adamo B et al (2014) Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. ASCO Meet Abstr 32((15_suppl)):2501","journal-title":"ASCO Meet Abstr"},{"issue":"8","key":"2884_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1470-2045(13)70162-1","volume":"14","author":"Y-J Ko","year":"2013","unstructured":"Ko Y-J, Canil CM, Mukherjee SD et al (2013) Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 14(8):769\u2013776. doi:\n                    10.1016\/S1470-2045(13)70162-1","journal-title":"Lancet Oncol"},{"issue":"(15_suppl)","key":"2884_CR29","first-page":"4504","volume":"33","author":"DI Quinn","year":"2015","unstructured":"Quinn DI, Ruel N, Twardowski P et al (2015) Eribulin in advanced urothelial cancer (AUC) patients (pts): a California cancer consortium trial\u2013NCI\/CTEP 7435. ASCO Meet Abstr 33((15_suppl)):4504","journal-title":"ASCO Meet Abstr"},{"issue":"10","key":"2884_CR30","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Mouw KW, Kim P et al (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4(10):1140\u20131153. doi:\n                    10.1158\/2159-8290.CD-14-0623","journal-title":"Cancer Discov"},{"key":"2884_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.009","author":"ER Plimack","year":"2015","unstructured":"Plimack ER, Dunbrack RL, Brennan TA et al (2015) Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. doi:\n                    10.1016\/j.eururo.2015.07.009","journal-title":"Eur Urol"},{"issue":"4","key":"2884_CR32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.eururo.2012.11.042","volume":"63","author":"G Sonpavde","year":"2013","unstructured":"Sonpavde G, Pond GR, Fougeray R et al (2013) Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 63(4):717\u2013723. doi:\n                    10.1016\/j.eururo.2012.11.042","journal-title":"Eur Urol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2884-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2884-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:15:50Z","timestamp":1589627750000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2884-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,13]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["2884"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2884-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2015,10,13]]},"assertion":[{"value":"29 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}